Immunic to Participate in Key Investor Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy IMUX?
Source: Newsfilter
- Investor Conference Schedule: Immunic will participate in the 26th Bio€quity Europe conference from May 4-6 and 12-13 in Prague, where CEO Daniel Vitt, Ph.D., and VP of Investor Relations Jessica Breu will host one-on-one investor meetings, aiming to enhance investor engagement and boost company visibility.
- Multiple Sclerosis Centers Annual Meeting: Immunic will attend the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting from May 27-29, where its management and medical teams will present a significant poster, further solidifying its expertise in the biotechnology sector and showcasing its commitment to neurological research.
- Poster Presentation Details: At the conference, Immunic will showcase three posters, including research on Vidofludimus Calcium, highlighting its safety and efficacy in multiple sclerosis patients, which is expected to attract considerable attention within the industry and enhance market recognition of the company's products.
- Clinical Trial Progress: Immunic's lead development program, Vidofludimus Calcium, is currently in phase 3 clinical trials, with top-line data expected by the end of 2026, which will positively impact the company's future market performance and investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMUX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMUX
Wall Street analysts forecast IMUX stock price to fall
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.620
Low
3.00
Averages
4.25
High
8.00
Current: 9.620
Low
3.00
Averages
4.25
High
8.00
About IMUX
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immunic, Inc. to Participate in Investor Conferences
- Clinical Trial Progress: Immunic, Inc.'s lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which will establish a foundation for the company's future market performance.
- Innovative Drug Mechanism: IMU-838 acts as a first-in-class Nurr1 activator, combining neuroprotective, anti-inflammatory, and antiviral effects by selectively inhibiting dihydroorotate dehydrogenase (DHODH), demonstrating potential across various neurological diseases.
- Diversified Development Pipeline: In addition to IMU-838, Immunic is developing earlier-stage programs like IMU-856 and IMU-381, aimed at building a broader therapeutic platform to address neurodegenerative, chronic inflammatory, and autoimmune-related diseases, enhancing the company's competitive edge.
- Investor Conference Participation: Immunic will participate in several investor and medical conferences in May to showcase its development progress and future strategies, aiming to attract more investor attention and enhance the company's visibility in the biotechnology sector.
See More
Immunic to Participate in Key Investor Conferences
- Investor Conference Schedule: Immunic will participate in the 26th Bio€quity Europe conference from May 4-6 and 12-13 in Prague, where CEO Daniel Vitt, Ph.D., and VP of Investor Relations Jessica Breu will host one-on-one investor meetings, aiming to enhance investor engagement and boost company visibility.
- Multiple Sclerosis Centers Annual Meeting: Immunic will attend the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting from May 27-29, where its management and medical teams will present a significant poster, further solidifying its expertise in the biotechnology sector and showcasing its commitment to neurological research.
- Poster Presentation Details: At the conference, Immunic will showcase three posters, including research on Vidofludimus Calcium, highlighting its safety and efficacy in multiple sclerosis patients, which is expected to attract considerable attention within the industry and enhance market recognition of the company's products.
- Clinical Trial Progress: Immunic's lead development program, Vidofludimus Calcium, is currently in phase 3 clinical trials, with top-line data expected by the end of 2026, which will positively impact the company's future market performance and investor confidence.
See More
Immunic Appoints New Chief Medical Officer
- Executive Change: Immunic, Inc. announced the appointment of Michael Panzara as Chief Medical Officer, succeeding Andreas Muehler, effective April 24, 2026, a move that will impact the company's strategic direction and development.
- Leadership Responsibilities: Panzara will lead the company's development organization, encompassing clinical development, medical affairs, and regulatory affairs, becoming a critical partner to the CEO and Board in defining and driving overall company strategy.
- Predecessor Background: Prior to joining Immunic, Panzara served as Chief Medical Officer at Neurvati Neurosciences, Inc., bringing extensive industry experience that will provide Immunic with new perspectives and expertise.
- Equity Incentive: To incentivize Panzara, Immunic's Compensation Committee granted him an initial equity option to purchase 300,000 shares of common stock, reflecting the company's expectations for his future contributions.
See More
Immunic Appoints New Chief Medical Officer to Drive Neurology Drug Development
- New Chief Medical Officer: Immunic appointed Dr. Michael A. Panzara as Chief Medical Officer effective April 24, 2026, to lead clinical development, medical affairs, and regulatory affairs, which is expected to enhance the company's strategy, particularly in pivotal trials for vidofludimus calcium.
- Extensive Industry Experience: Dr. Panzara brings over 25 years of global neurology experience, having successfully overseen global regulatory approvals for multiple sclerosis drugs at Sanofi Genzyme and Biogen, which is anticipated to add significant value to Immunic's clinical programs.
- Clinical Trial Progress: His leadership will support Immunic in achieving critical data from the phase 3 ENSURE trials for relapsing multiple sclerosis, with top-line results expected by the end of 2026, which is crucial for the company's commercialization strategy.
- Equity Incentive Plan: As an inducement for joining, Immunic's Board granted Dr. Panzara options to purchase 300,000 shares of common stock, vesting in two stages, reflecting the company's high regard and expectations for his leadership capabilities.
See More
Immunic Appoints New Chief Medical Officer to Advance Neurology Programs
- New Chief Medical Officer: Immunic appointed Dr. Michael A. Panzara as Chief Medical Officer effective April 24, 2026, to lead clinical development, medical affairs, and regulatory affairs, which is expected to drive the pivotal development of vidofludimus calcium and support the company's transition to a fully integrated commercial entity.
- Extensive Industry Experience: Dr. Panzara brings over 25 years of global neurology experience, having successfully overseen global regulatory approvals for multiple sclerosis drugs at Sanofi Genzyme and Biogen, which is anticipated to provide significant strategic support for Immunic's clinical programs.
- Clinical Trial Progress: Under Panzara's leadership, Immunic will advance vidofludimus calcium through the phase 3 ENSURE trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which is crucial for the company's future market positioning.
- Equity Incentive Plan: Immunic's Board granted Dr. Panzara an initial equity option to purchase 300,000 shares of common stock as an inducement for his employment, reflecting the company's commitment to attracting top talent to drive its growth.
See More
Immunic to Implement Reverse Stock Split Effective April 27, 2026
- Reverse Stock Split: Immunic has announced a reverse stock split effective April 27, 2026, aimed at increasing the per-share price by reducing the number of outstanding shares, thereby meeting contractual obligations.
- Contractual Obligations: The reverse split is primarily intended to fulfill the company's commitments under a securities purchase agreement signed with certain institutional and accredited investors on February 12, 2026, ensuring financial compliance.
- Market Reaction: Following the announcement of the reverse split, Immunic's stock price fell by 4.42% in premarket trading, indicating a cautious market response that could impact investor confidence.
- Financing Background: Recently, Immunic completed a $400 million private placement, and despite facing stock price pressure, the company is actively seeking to drive future growth through new assets and leadership transitions.
See More
Immunic, Inc. to Participate in Investor Conferences
- Clinical Trial Progress: Immunic, Inc.'s lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which will establish a foundation for the company's future market performance.
- Innovative Drug Mechanism: IMU-838 acts as a first-in-class Nurr1 activator, combining neuroprotective, anti-inflammatory, and antiviral effects by selectively inhibiting dihydroorotate dehydrogenase (DHODH), demonstrating potential across various neurological diseases.
- Diversified Development Pipeline: In addition to IMU-838, Immunic is developing earlier-stage programs like IMU-856 and IMU-381, aimed at building a broader therapeutic platform to address neurodegenerative, chronic inflammatory, and autoimmune-related diseases, enhancing the company's competitive edge.
- Investor Conference Participation: Immunic will participate in several investor and medical conferences in May to showcase its development progress and future strategies, aiming to attract more investor attention and enhance the company's visibility in the biotechnology sector.
See More
Immunic to Participate in Key Investor Conferences
- Investor Conference Schedule: Immunic will participate in the 26th Bio€quity Europe conference from May 4-6 and 12-13 in Prague, where CEO Daniel Vitt, Ph.D., and VP of Investor Relations Jessica Breu will host one-on-one investor meetings, aiming to enhance investor engagement and boost company visibility.
- Multiple Sclerosis Centers Annual Meeting: Immunic will attend the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting from May 27-29, where its management and medical teams will present a significant poster, further solidifying its expertise in the biotechnology sector and showcasing its commitment to neurological research.
- Poster Presentation Details: At the conference, Immunic will showcase three posters, including research on Vidofludimus Calcium, highlighting its safety and efficacy in multiple sclerosis patients, which is expected to attract considerable attention within the industry and enhance market recognition of the company's products.
- Clinical Trial Progress: Immunic's lead development program, Vidofludimus Calcium, is currently in phase 3 clinical trials, with top-line data expected by the end of 2026, which will positively impact the company's future market performance and investor confidence.
See More
Immunic Appoints New Chief Medical Officer
- Executive Change: Immunic, Inc. announced the appointment of Michael Panzara as Chief Medical Officer, succeeding Andreas Muehler, effective April 24, 2026, a move that will impact the company's strategic direction and development.
- Leadership Responsibilities: Panzara will lead the company's development organization, encompassing clinical development, medical affairs, and regulatory affairs, becoming a critical partner to the CEO and Board in defining and driving overall company strategy.
- Predecessor Background: Prior to joining Immunic, Panzara served as Chief Medical Officer at Neurvati Neurosciences, Inc., bringing extensive industry experience that will provide Immunic with new perspectives and expertise.
- Equity Incentive: To incentivize Panzara, Immunic's Compensation Committee granted him an initial equity option to purchase 300,000 shares of common stock, reflecting the company's expectations for his future contributions.
See More
Immunic Appoints New Chief Medical Officer to Drive Neurology Drug Development
- New Chief Medical Officer: Immunic appointed Dr. Michael A. Panzara as Chief Medical Officer effective April 24, 2026, to lead clinical development, medical affairs, and regulatory affairs, which is expected to enhance the company's strategy, particularly in pivotal trials for vidofludimus calcium.
- Extensive Industry Experience: Dr. Panzara brings over 25 years of global neurology experience, having successfully overseen global regulatory approvals for multiple sclerosis drugs at Sanofi Genzyme and Biogen, which is anticipated to add significant value to Immunic's clinical programs.
- Clinical Trial Progress: His leadership will support Immunic in achieving critical data from the phase 3 ENSURE trials for relapsing multiple sclerosis, with top-line results expected by the end of 2026, which is crucial for the company's commercialization strategy.
- Equity Incentive Plan: As an inducement for joining, Immunic's Board granted Dr. Panzara options to purchase 300,000 shares of common stock, vesting in two stages, reflecting the company's high regard and expectations for his leadership capabilities.
See More
Immunic Appoints New Chief Medical Officer to Advance Neurology Programs
- New Chief Medical Officer: Immunic appointed Dr. Michael A. Panzara as Chief Medical Officer effective April 24, 2026, to lead clinical development, medical affairs, and regulatory affairs, which is expected to drive the pivotal development of vidofludimus calcium and support the company's transition to a fully integrated commercial entity.
- Extensive Industry Experience: Dr. Panzara brings over 25 years of global neurology experience, having successfully overseen global regulatory approvals for multiple sclerosis drugs at Sanofi Genzyme and Biogen, which is anticipated to provide significant strategic support for Immunic's clinical programs.
- Clinical Trial Progress: Under Panzara's leadership, Immunic will advance vidofludimus calcium through the phase 3 ENSURE trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which is crucial for the company's future market positioning.
- Equity Incentive Plan: Immunic's Board granted Dr. Panzara an initial equity option to purchase 300,000 shares of common stock as an inducement for his employment, reflecting the company's commitment to attracting top talent to drive its growth.
See More
Immunic to Implement Reverse Stock Split Effective April 27, 2026
- Reverse Stock Split: Immunic has announced a reverse stock split effective April 27, 2026, aimed at increasing the per-share price by reducing the number of outstanding shares, thereby meeting contractual obligations.
- Contractual Obligations: The reverse split is primarily intended to fulfill the company's commitments under a securities purchase agreement signed with certain institutional and accredited investors on February 12, 2026, ensuring financial compliance.
- Market Reaction: Following the announcement of the reverse split, Immunic's stock price fell by 4.42% in premarket trading, indicating a cautious market response that could impact investor confidence.
- Financing Background: Recently, Immunic completed a $400 million private placement, and despite facing stock price pressure, the company is actively seeking to drive future growth through new assets and leadership transitions.
See More
